Table 1. Combination of anti-angiogenetictherapy and immunotherapy clinical trials.

Phase	Anti-angiogenesis drug	Immunecheckpoints blocker	Design	Primary endpoint(s)	Clinical trail ID
I	Angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR Α/Β (nintedanib)	IGG4 anti-PD-1 blocking mAb (pembrolizumab)	Pembrolizumab + nintedanib (PEMBIB) in second line HCC	Maximum tolerated dose and dose limiting toxicities	NCT02856425
I	Anti-VEGFR2 antibody (ramucirumab)	Anti–PD-L1 immune checkpoint inhibitor (MEDI4736)	Ramucirumab + MEDI4736 in metastatic or locally advanced and unresectable HCC	Dose limiting toxicities	NCT02572687
I/II	VEGFR2-TKI (apatinib)	Anti-PD-1 mAb (SHR-1210)	Apatinib + SHR-1210 in advanced HCC	Overall survival rate	NCT02942329
III	VEGFR –TKI (sorafenib)	Pexastimogene devacirepvec (Pexa-Vec)	Sorafenib VS sorafenib + Pexa-Vac in advanced HCC	Overall survival	NCT02562755

Abbreviation – FGFR: fibroblast growth factor receptor; HCC: hepatocellular carcinoma; mAb: monoclonal antibody; PDGFR: platlet derived growth factor receptor; TKI: tyrosin kinase inhibitor; VEGFR: vascular endothelial growth factor receptor.